MedTrace Logo

A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999

NCT01530529 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2012-05-01

No results posted yet for this study

Summary

The purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of PF-05180999 relative to an immediate-release formulation in healthy adult subjects. Two doses of the modified-release formulation and one dose of the immediate-release formulation will be evaluated under fasted conditions. One dose of the modified-release formulation will also be evaluated in the presence of food.

Conditions

  • Healthy

Interventions

DRUG

PF-05180999

Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation

DRUG

PF-05180999

Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation

DRUG

PF-05180999

Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation

DRUG

PF-05180999

Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01530529 on ClinicalTrials.gov